Who is sponsoring NCT06686043?

NCT06686043 is sponsored by Baylor College of Medicine.

What drugs are being tested in NCT06686043?

Interventions in NCT06686043: HPV vaccine, Imiquimod, and metformin combination therapy.

What condition does NCT06686043 study?

NCT06686043 studies Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma.

Is NCT06686043 still recruiting?

NCT06686043 is currently recruiting now. Last updated 13 November 2024.

Last reviewed 2024-11-13 · How we verify

NCT06686043: HPV-VIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HPV Vaccine, Imiquimod, and Metformin Combination Trial

Recruiting now Phase 2 Last updated 13 November 2024

What this trial tests

Phase 2 trial testing HPV vaccine, Imiquimod, and metformin combination therapy in Cervical Carcinoma in 85 participants. Currently enrolling.

Timeline

23 August 2024

Primary endpoint
23 August 2026

23 August 2028

Quick facts

Lead sponsor	Baylor College of Medicine
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	85
Start date	23 August 2024
Primary completion	23 August 2026
Estimated completion	23 August 2028
Sites	2 locations across United States

Drugs / interventions tested

HPV vaccine, Imiquimod, and metformin combination therapy — full drug profile →

Conditions studied

Cervical Carcinoma — all drugs for Cervical Carcinoma →
Vaginal Carcinoma — all drugs for Vaginal Carcinoma →
Vulvar Carcinoma — all drugs for Vulvar Carcinoma →
HPV (Human Papillomavirus)-Associated Carcinoma — all drugs for HPV (Human Papillomavirus)-Associated Carcinoma →

Sponsor

Baylor College of Medicine

Who can join

Adults 18 to 64, female only, with Cervical Carcinoma or Vaginal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are: Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone. Participants will: Receive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation. Have blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit. Take a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Senescent immune cells in the tumor microenvironment: emerging insights into cancer immunotherapy resistance.
Gao D, Kan P, He Y, Sun S, et al · · 2025 · cited 5× · PMID 41181123 · DOI 10.3389/fimmu.2025.1656733
Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review).
Zhou X, An R, Li X. · · 2026 · PMID 41246557 · DOI 10.3892/ol.2025.15375

Verify or expand the search:

Other recruiting trials for Cervical Carcinoma

Currently open trials in the same condition.

NCT07407647 — Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Baylor College of Medicine trials

Trials by the same sponsor.

NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06686043 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
Last refreshed: 13 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06686043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing